Last Updated : February 21, 2024
Details
Review Type: Rapid
Provisional Funding Algorithm |
|
---|---|
Draft Report Posted: | December 07, 2023 |
Stakeholder Feedback Deadline: | December 14, 2023 |
Final Report Posted: | 21 February , 2024 |
Review Type: Rapid
Provisional Funding Algorithm |
|
---|---|
Draft Report Posted: | December 07, 2023 |
Stakeholder Feedback Deadline: | December 14, 2023 |
Final Report Posted: | 21 February , 2024 |
Call for patient/clinician input open | November 29, 2023 |
---|---|
Call for patient/clinician input closed | January 29, 2024 |
Call for industry input open | November 29, 2023 |
Call for industry input closed | January 29, 2024 |
Submission received | October 24, 2023 |
Review initiated | October 25, 2023 |
Expert committee meeting (initial) | May 10, 2024 |
Draft recommendation posted for stakeholder feedback | June 06, 2024 |
End of feedback period | June 20, 2024 |
Final recommendation posted | July 24, 2024 |
Canada's Drug Agency review report(s) posted | July 16, 2024 |
Review Type: Panel
Provisional Funding Algorithm |
|
---|---|
Draft Report Posted: | November 30, 2023 |
Stakeholder Feedback Deadline: | December 07, 2023 |
Final Report Posted: | January 24,2024 |
Call for patient/clinician input open | November 14, 2023 |
---|---|
Call for patient/clinician input closed | January 12, 2024 |
Clarification: - Patient input submission received from Canadian XLH Network | |
Submission received | January 02, 2024 |
Submission accepted | January 16, 2024 |
Review initiated | January 17, 2024 |
Draft CADTH review report(s) provided to sponsor for comment | April 04, 2024 |
Deadline for sponsors comments | April 15, 2024 |
CADTH review report(s) and responses to comments provided to sponsor | May 09, 2024 |
Expert committee meeting (initial) | May 22, 2024 |
Draft recommendation issued to sponsor | June 04, 2024 |
Draft recommendation posted for stakeholder feedback | June 13, 2024 |
End of feedback period | June 27, 2024 |
Clarification: - Reconsideration: minor revisions requested by drug programs - Request for reconsideration accepted - Reconsideration: major revisions requested by drug programs - Request for reconsideration accepted | |
Expert committee meeting | September 25, 2024 |
Final recommendation issued to sponsor and drug plans | October 10, 2024 |
Final recommendation posted | October 29, 2024 |
Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | October 25, 2024 |
CADTH review report(s) posted | February 12, 2025 |
Call for patient/clinician input open | November 09, 2023 |
---|---|
Call for patient/clinician input closed | January 08, 2024 |
Call for industry input open | November 09, 2023 |
Call for industry input closed | January 08, 2024 |
Submission received | October 24, 2023 |
Review initiated | October 25, 2023 |
Expert committee meeting (initial) | May 10, 2024 |
Draft recommendation posted for stakeholder feedback | June 06, 2024 |
End of feedback period | June 20, 2024 |
Final recommendation posted | August 01, 2024 |
Canada's Drug Agency review report(s) posted | August 01, 2024 |
Call for patient/clinician input open | November 09, 2023 |
---|---|
Call for patient/clinician input closed | January 08, 2024 |
Call for industry input open | November 09, 2023 |
Call for industry input closed | January 08, 2024 |
Submission received | October 24, 2023 |
Review initiated | October 25, 2023 |
Expert committee meeting (initial) | May 10, 2024 |
Final recommendation posted | August 01, 2024 |
Canada's Drug Agency review report(s) posted | August 01, 2024 |
Call for patient/clinician input open | November 08, 2023 |
---|---|
Call for patient/clinician input closed | January 08, 2024 |
Clarification: - Patient input submission received from Schizophrenia Society of Canada | |
Submission received | December 20, 2023 |
Submission accepted | January 11, 2024 |
Review initiated | January 12, 2024 |
Draft CADTH review report(s) provided to sponsor for comment | April 08, 2024 |
Deadline for sponsors comments | April 17, 2024 |
CADTH review report(s) and responses to comments provided to sponsor | May 09, 2024 |
Expert committee meeting (initial) | May 22, 2024 |
Clarification: Recommendation deferred to June 26, 2024 CDEC meeting | |
Draft recommendation issued to sponsor | July 10, 2024 |
Draft recommendation posted for stakeholder feedback | July 18, 2024 |
End of feedback period | August 01, 2024 |
Final recommendation issued to sponsor and drug plans | August 15, 2024 |
Final recommendation posted | September 03, 2024 |
Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | August 29, 2024 |
CADTH review report(s) posted | January 16, 2025 |
Call for patient/clinician input open | October 30, 2023 |
---|---|
Call for patient/clinician input closed | December 22, 2023 |
Clarification: - Patient input submission received from Lung Cancer Canada and the Lung Health Foundation | |
Submission received | December 11, 2023 |
Submission accepted | January 02, 2024 |
Clarification: - Additional information has been received and the temporary suspension of the review has been lifted | |
Review initiated | January 03, 2024 |
Draft CADTH review report(s) provided to sponsor for comment | June 21, 2024 |
Deadline for sponsors comments | July 03, 2024 |
CADTH review report(s) and responses to comments provided to sponsor | August 01, 2024 |
Expert committee meeting (initial) | August 14, 2024 |
Draft recommendation issued to sponsor | August 26, 2024 |
Draft recommendation posted for stakeholder feedback | September 05, 2024 |
End of feedback period | September 19, 2024 |
Final recommendation issued to sponsor and drug plans | October 03, 2024 |
Final recommendation posted | October 22, 2024 |
Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | October 18, 2024 |
CADTH review report(s) posted | January 29, 2025 |